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Cervical artery dissection in patients $60
years
Often painless, few mechanical triggers
ABSTRACT
Objective: In a cohort of patients diagnosed with cervical artery dissection (CeAD), to determine
the proportion of patients aged $60 years and compare the frequency of characteristics (pre-
senting symptoms, risk factors, and outcome) in patients aged ,60 vs $60 years.
Methods: We combined data from 3 large cohorts of consecutive patients diagnosed with CeAD
(i.e., Cervical Artery Dissection and Ischemic Stroke Patients–Plus consortium). We dichotomized
cases into 2 groups, age$60 and ,60 years, and compared clinical characteristics, risk factors,
vascular features, and 3-month outcome between the groups. First, we performed a combined
analysis of pooled individual patient data. Secondary analyses were done within each cohort and
across cohorts. Crude and adjusted odds ratios (OR [95% confidence interval]) were calculated.
Results: Among 2,391 patients diagnosed with CeAD, we identified 177 patients (7.4%) aged
$60 years. In this age group, cervical pain (ORadjusted 0.47 [0.33–0.66]), headache (ORadjusted
0.58 [0.42–0.79]), mechanical trigger events (ORadjusted 0.53 [0.36–0.77]), and migraine
(ORadjusted 0.58 [0.39–0.85]) were less frequent than in younger patients. In turn, hypercholes-
terolemia (ORadjusted 1.52 [1.1–2.10]) and hypertension (ORadjusted 3.08 [2.25–4.22]) were more
frequent in older patients. Key differences between age groups were confirmed in secondary
analyses. In multivariable, adjusted analyses, favorable outcome (i.e., modified Rankin Scale score
0–2) was less frequent in the older age group (ORadjusted 0.45 [0.25, 0.83]).
Conclusion: In our study population of patients diagnosedwith CeAD, 1 in 14was aged$60 years. In
these patients, pain and mechanical triggers might be missing, rendering the diagnosis more challeng-
ing and increasing the risk ofmissedCeADdiagnosis in older patients.Neurology®2017;88:1313–1320
GLOSSARY
CADISP-Plus 5 Cervical Artery Dissection and Ischemic Stroke Patients–Plus; CeAD 5 cervical artery dissection; CI 5 confi-
dence interval; IPD 5 individual patient data; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; OR 5 odds ratio.
Cervical artery dissection (CeAD) is uncommon in the general population, but it is a major
cause of stroke in the young.1,2 The majority of patients with CeAD are aged 40–50 years at
CeAD occurrence.1,3 In patients aged 60 years and above, atherosclerosis, small vessel disease, or
cardioembolism dominate as mechanisms of ischemic stroke.4 Although there are few reports
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about CeAD in patients in their 60s and
70s,5,6 the frequency of characteristics (pre-
senting symptoms, risk factors, and outcome)
in this age group of patients with CeAD re-
mains unknown.
The profile of patients with CeAD seems to
be different in younger and older age groups.7
For CeAD patients $60 years, an age group
where CeAD is considered less frequent, it
remains unknown if clinical characteristics,
vascular findings, and 3-month outcome differ
compared to younger patients. Such data are
clinically important: first, CeAD is commonly
thought of as a disease in the young1 and
therefore clinicians might not consider CeAD
in older patients. Second, knowledge of the
characteristics of CeAD for patients$60 years
is important to inform appropriate diagnostic
and treatment decisions in the older age group.
With these considerations in mind, we
aimed to (1) determine the proportion of pa-
tients with CeAD aged $60 years and (2)
identify the characteristics of patients with
CeAD aged$60 years compared to those aged
,60 years. We analyzed the extended dataset
of the multicenter Cervical Artery Dissection
and Ischemic Stroke Patients–Plus (CADISP-
Plus) consortium.8,9
METHODS Study population and data collection. The
updated dataset of the multicenter CADISP-Plus consortium
comprises 2,426 patients with CeAD including patients from
the CADISP clinical study (CADISP-1 cohort: n 5 983
patients and CADISP-2 cohort [US centers]: n 5 312 patients)
and the Paris-Lariboisière/Zurich/Bern CeAD registry (n 5
1,131 patients). The detailed structure and methods of each of
these clinical cohorts have been described in detail.9–11 All sites
from these cohorts applied the same widely accepted diagnostic
CeAD criteria and definitions of key variables allowing pooled
analyses.8 There was, however, no standardized surveillance across
cohorts and age groups (i.e., standardized assessments were not
uniformly performed on all stroke patients to assess for CeAD). In
brief, diagnostic criteria of CeAD (for internal carotid or vertebral
artery) were defined as follows: presence of a mural hematoma,
aneurysmal dilation, long tapering stenosis, intimal flap, double
lumen, or occlusion situated.2 cm above the carotid bifurcation
revealing an aneurysmal dilation or a long tapering stenosis after
recanalization.8 An overview of the cohorts is given in the e-
Methods at Neurology.org.
Patient characteristics and variable definitions. The follow-
ing demographic, clinical, and imaging data were obtained for
individual patients from each cohort as done in previous
research8,12,13: age, sex, vascular risk factors according to predefined
criteria (i.e., presence or absence of hypertension, hypercholesterol-
emia, and diabetes),14 site of dissection (i.e., internal carotid artery,
vertebral artery, both internal carotid and vertebral artery),15
pathologic features of the dissected artery (i.e., presence or absence
of a vessel occlusion),15 presenting symptoms including ischemic
stroke, TIA, and local signs and symptoms (i.e., Horner syndrome,
headache, and cervical pain),13 presence or absence of putative
CeAD risk factors (i.e., migraine16 and prior mechanical trigger
events12), and stroke severity as assessed by the NIH Stroke Scale
score (NIHSS). Functional outcome was assessed during outpatient
visits or telephone calls using the modified Rankin Scale (mRS) at 3
months. Excellent functional outcome was defined as an mRS score
of 0–1, favorable outcome as an mRS score of 0–2. Patients with
a history of polytrauma within the prior 4 weeks were excluded from
the current analysis. Detailed definitions of each of these variables
were published previously.8,9,11
Statistical analyses. Patient baseline demographic and clinical
data were compared between patients with CeAD aged$60 years
and those ,60 years. First, we compared variables between
groups (i.e., $60 vs ,60) across all patients from every cohort
in the form of a combined analysis based on pooled individual
patient data (IPD). For categorical variables, differences between
groups were assessed using the x2 test, or the Fisher exact test if
suitable. Differences in continuous variables were calculated using
the Mann-Whitney test. Multivariable logistic regression analysis
was performed with adjustment for sex and site of dissection (i.e.,
internal carotid vs vertebral artery dissection).7 For analysis of 3-
month outcome, we adjusted for stroke severity (NIHSS) and
occlusion of the dissected artery as the most important
outcome predictors in CeAD.17 Based on the results of the
univariate analyses, we also adjusted for diagnoses of
hypertension and hypercholesterolemia. A p value ,0.05 was
considered statistically significant.
For the secondary analyses, we performed (1) univariate and
adjusted multivariable comparisons between age groups within
each separate cohort and (2) meta-analyses across all 3 clinical co-
horts by using a fixed-effects Mantel-Haenszel model with calcu-
lation of odds ratios (ORs) and corresponding 95% confidence
intervals (CIs). Heterogeneity across study cohorts was assessed
using the I2 index. As post hoc analyses we compared patients
aged#45 years to those aged$65 years in unadjusted, univariate
comparisons on the IPD dataset.
Standard protocol approvals, registrations, and patient
consents. Local authorities and ethics committees approved pro-
tocols for the included cohorts from all participating centers. Data
collection and analyses were conducted according to national
rules of approval and informed consent of the included patients.
RESULTS Patient demographics. A total of 2,391 pa-
tients with CeAD out of 2,426 patients were eligible
for analysis. Among these, we identified 177 (7.4%)
patients aged $60 years. The overall median age of
all consecutive patients with CeAD included in this
study was 45 years (interquartile range 38–52).
Patient demographics and clinical characteristics are
presented in table 1 (across all patients) and tables e-1
through e-3 (separately for each study cohort). In
patients aged $60 years, male patients were predom-
inant (67.8% of those $60 years old vs 55.8% ,60
years old; punadjusted 5 0.002; table 1).
Patient clinical characteristics and putative risk factors.
Combined analysis of pooled IPD and meta-analysis across
study cohorts. Patients aged $60 years presented less
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Table 1 Combined analysis of pooled individual patient data from all clinical cohorts (CADISP-1, CADISP-2, PZB)
All patients (n 5 2,391) <60 y (n 5 2,214) ‡60 y (n 5 177)
‡60 y vs<60 y, unadjusted analysis ‡60 y vs <60 y, adjusted analysis
p Value OR (95% CI) p Value OR (95% CI)
Sex, female (%) 1,036/2,391 (43.3) 979/2,214 (44.2) 57/177 (32.2) 0.002a 0.6 (0.43–0.83) NA
Age, y, median (IQR) 45 (38–52) 44 (37–50) 63 (61–67) NA NA
Mechanical trigger event, n (%)b 744/2,370 (31.4) 708/2,193 (32.3) 36/177 (20.3) 0.001a 0.54 (0.37–0.78) 0.001a 0.53 (0.36–0.77)
Migraine, n (%)b 739/2,358 (31.3) 704/2,183 (32.2) 35/175 (20) 0.001a 0.53 (0.36–0.77) 0.005a 0.58 (0.39–0.85)
Hypercholesterolemia, n (%)c 727/2,174 (33.4) 655/2,009 (32.6) 72/165 (43.6) 0.004a 1.6 (1.16–2.21) 0.011a 1.52 (1.1–2.10)
Hypertension, n (%)c 621/2,341 (26.5) 531/2,165 (24.5) 90/176 (51.1) ,0.001a 3.22 (2.36–4.4) ,0.00a 3.08 (2.25–4.22)
Diabetes, n (%)c 66/2,346 (2.8) 51/2,170 (2.4) 15/176 (8.5) ,0.001a 3.87 (2.13–7.04) ,0.001a 3.80 (2.09–6.93)
Ischemic stroke or TIA, n (%)b 1,682/2,391 (70.3) 1,565/2,214 (70.7) 117/177 (66.1) 0.199 0.81 (0.59–1.12) 0.218 0.81 (0.59–1.13)
Horner syndrome, n (%)b 715/2,362 (30.3) 660/2,186 (30.2) 55/176 (31.3) 0.769 1.05 (0.75–1.46) 0.832 0.96 (0.68–1.36)
Cervical pain, n (%)b 1,048/2,359 (44.4) 999/2,183 (45.8) 49/176 (27.8) ,0.001a 0.46 (0.33–0.64) ,0.001a 0.47 (0.33–0.66)
Headache, n (%)b 1,579/2,360 (66.9) 1,484/2,185 (67.9) 95/175 (54.3) ,0.001a 0.56 (0.41–0.77) 0.001a 0.58 (0.42–0.79)
Occlusion, n (%)b 805/2,381 (33.8) 752/2,214 (34) 53/167 (31.7) 0.557 0.90 (0.65–1.27) 0.454 0.88 (0.63–1.23)
NIHSS at admission, mean (6SD)d 6.3 (6.9) 6.4 (7) 5.4 (6) 0.168 0.98 (0.95–1.01) 0.136 0.97 (0.94–1.01)
Excellent outcome (mRS 0–1), n (%)e 1,490/2,025 (73.6) 1,377/1,868 (73.7) 113/157 (72) 0.635 0.92 (0.64–1.32) 0.155 0.71 (0.45–1.14)
Favorable outcome (mRS 0–2), n (%)e 1,769/2,025 (87.4) 1,638/1,868 (87.7) 131/157 (83.4) 0.124 0.71 (0.45–1.10) 0.01a 0.45 (0.25–0.83)
Internal carotid artery dissection, n (%)c 1,603/2,391 (67) 1,479/2,214 (66.8) 124/177 (70.1) 0.375 1.16 (0.83–1.62) 0.502 1.12 (0.80–1.57)
Vertebral artery dissection, n (%)c 889/2,391 (37.2) 829/2,214 (37.4) 60/177 (33.9) 0.348 0.86 (0.62–1.18) 0.520 0.9 (0.95–1.24)
Abbreviations: CADISP 5 Cervical Artery Dissection and Ischemic Stroke Patients; CI 5 confidence interval; IQR 5 interquartile range; mRS 5 modified Rankin Scale; NA 5 not applicable; NIHSS 5 NIH Stroke
Scale; OR 5 odds ratio; PZB 5 Paris-Lariboisière/Zurich/Bern CeAD registry.
Demographics, clinical baseline characteristics, and outcome are presented across all patients. Comparisons are between patients aged ,60 and $60 years in unadjusted and adjusted analyses. Numbers for
internal carotid and vertebral artery dissection include patients presenting with multiple artery dissection. Data may not be available for all patients, leading to different total numbers of patients for each variable.
aSignificant.
bAdjusted for sex and internal carotid artery as site of dissection.
cAdjusted for sex.
dAdjusted for sex and internal carotid artery as site of dissection (in patients with any cerebral ischemia [ischemic stroke or TIA]).
e Adjusted for sex, internal carotid artery as site of dissection, occlusion of the dissected artery, NIHSS at baseline, and diagnoses of hypertension and hypercholesterolemia.
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Figure 1 Forest plots of the meta-analyses across all 3 clinical cohorts (Cervical Artery Dissection and Ischemic
Stroke Patients [CADISP]–1, CADISP-2, and Paris-Lariboisière/Zurich/Bern CeAD registry [PZB])
(A–F) Frequency of patient characteristics were compared between patients aged $60 years and ,60 years. A fixed-
effects Mantel-Haenszel (M-H) model was used, with calculation of unadjusted odds ratios (ORs) and corresponding 95%
confidence intervals (CIs). Heterogeneity across study cohorts was assessed using the I2 index. Results of those analyses
showing significant differences between the age groups are presented.
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frequently with cervical pain or headache (cervical
pain, IPD: ORadjusted 0.47 [0.33–0.66]; headache,
IPD: ORadjusted 0.58 [0.42–0.79]) (table 1 and figure
1). In contrast, an equal proportion of patients in each
age group presented with Horner syndrome (31.3%
[$60 years] vs 30.2% [,60 years]). This held true
for Horner syndrome in the absence of pain, other local
signs of CeAD (i.e., tinnitus, cranial nerve palsy), or
mechanical trigger events (n5 8 [20%, age$60 years]
vs n 5 54 [26.7%, age ,60 years], punadjusted 5
0.884). Likewise, cerebral ischemic events (i.e., ische-
mic stroke or TIA) at CeAD onset occurred at similar
rates in both young and older patients with CeAD
(table 1 and figure e-1).
Mechanical trigger events prior to CeAD onset
were significantly less common in patients aged
$60 years (IPD: ORadjusted 0.53 [0.36–0.77]; table
1). Migraine was also less frequent in older patients
with CeAD (IPD: ORadjusted 0.58 [0.39–0.85]; table
1). In contrast, hypercholesterolemia (IPD: ORadjusted
1.52 [1.1–2.10]), hypertension (IPD: ORadjusted 3.08
[2.25–4.22]), and diabetes (IPD: ORadjusted 3.8
[2.09–6.93]) were more common in patients with
CeAD aged $60 years.
For the distribution of the site of dissection (inter-
nal carotid or vertebral artery), as well as the occlusion
of the dissected artery, there was no significant differ-
ence between the 2 age groups in primary (IPD) or
secondary analyses (table 1, tables e-1 through e-3,
and figure e-1). Post hoc analyses of the first antith-
rombotic treatment after CeAD diagnosis revealed
the following results: overall, 2,191 patients
(91.6%) received any antithrombotic therapy after
diagnosis of CeAD (n5 164 [92.7% of patients aged
$60] and n5 2,027 [91.6% of patients aged,60]).
Anticoagulants were used significantly less often in
patients aged $60 years (patients receiving anticoa-
gulants: n 5 82 [50%, age $60] vs n 5 1,295
[63.9%, age ,60], punadjusted ,0.001).
Unadjusted analysis of favorable functional out-
come (i.e., mRS 0–2) at 3 months did not show
a difference between the age groups (IPD: ORunad-
justed 0.71 [0.45–1.10]). However, after adjustment
(for sex, site of dissection, occlusion of the dissected
artery, NIHSS, hypertension, and hypercholesterol-
emia), the analysis revealed a lower likelihood of
a favorable outcome in patients with CeAD aged
$60 years (IPD: ORadjusted 0.45 [0.25, 0.83])
(table 1).
Key findings on differences between age groups
showed similar results in primary analyses (of com-
bined data and within each cohort) as well as the sec-
ondary analyses (in meta-analyses across cohorts). To
look for extremes of effect, we further performed
unadjusted post hoc analyses comparing characteris-
tics of patients aged #45 years to those aged $65
years (i.e., removing those aged 46–64 years old). We
focused on variables that showed statistically signifi-
cant differences between age groups in our primary
analyses. This post hoc analyses mainly confirmed our
primary results, with all associations being in the same
direction of effect, and only the frequency of mechan-
ical trigger events losing significance (punadjusted 5
0.073; table e-4).
Detailed information on the distribution of char-
acteristics and risk factors are given in table 1 and
tables e-1 through e-4, as well as figure 1 and figure
e-1.
DISCUSSION In this large compilation of individual
data of patients diagnosed with CeAD, our analyses
on proportion and characteristics of patients with
CeAD aged $60 years revealed the following key
findings. First, 7% of the patients with CeAD in
our study population were aged $60 years. Second,
in the studied population, compared to those aged
,60 years, patients with CeAD aged $60 years were
more often male, but were less likely to have painful
CeAD, a preceding mechanical trigger event, or a his-
tory of migraine. Third, in this population, age $60
years was independently associated with less favorable
outcome after CeAD.
Until now, the frequency of patients aged $60
years among patients with CeAD has not been sys-
tematically studied. In a small CeAD cohort, over
30% (11 of 34) of patients with CeAD were reported
to be aged .60 years.6 Although limited by a small
sample size, this number indicated that CeAD in
elderly patients might occur more frequently than
suspected in a disease characterized as primarily
affecting younger age groups.1–3 Our analysis of
a large, multicenter dataset found that 1 out of 14
patients with CeAD was 60 years or older. The 95%
CI (6.4–8.5) in our analysis indicated that this rate
could even be as high as every 11th CeAD patient. In
addition, there was a clear male preponderance in this
age group, in line with previous findings.7
Cervical pain and headache are common local
symptoms in patients with CeAD.11,15 However,
our analysis revealed that cervical pain is not a hall-
mark of CeAD in patients $60 years. We can only
speculate on the reasons for this observation. Pain in
CeAD most likely arises directly from the irritation of
nerves surrounding the dissected vessel.18,19 An age-
related decrease in nociceptors might be a hypothetical
explanation for this observation. In addition, there is
evidence of the association of increasing age with
increasing arterial (carotid) stiffness.20 Increasing arte-
rial stiffness in older patients leading to a decreased
distensibility of the cervical arteries may play a role in
a reduction of periarterial nerve irritation in CeAD
and thereby a reduction of painful local symptoms.
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Older patients with CeAD less frequently report
a history of migraine. Migraine—in particular without
aura—has been associated with CeAD in prior studies.
Compared to age- and sex-matched ischemic stroke
patients without CeAD, a history of migraine was sig-
nificantly more common among patients with
CeAD.16,21 In the general population, migraine is most
common among middle-aged adults,22 and it is more
common among female patients.22,23 Thus, the effect
seen in our analysis may reflect the age and sex distri-
bution of migraine in the general population. In turn,
hypertension and hypercholesterolemia were signifi-
cantly more common among older patients with CeAD
compared to younger ones. In general, compared to
age- and sex-matched healthy referents, patients with
CeAD are more frequently hypertensive but show
a lower prevalence of hypercholesterolemia.14
In patients with CeAD aged $60 years, mechan-
ical trigger events were reported only in one fifth of
patients, which is significantly less frequent than in
younger patients (one third). Mechanical trigger
events seem to play an important role in CeAD path-
ophysiology, as they are significantly more prevalent
in CeAD as compared to ischemic stroke patients
without CeAD and healthy subjects.12 The underly-
ing reason for a lower frequency of such trigger events
in older patients remains elusive. It might point at
a less physically active lifestyle of older patients,
thereby reducing the risk of CeAD in older individ-
uals. However, age-dependent differences in patho-
physiology of CeAD cannot be ruled out. For
instance, the dissecting mechanism of CeAD in older
patients may arise intrinsically in the artery rather
than from external forces.24 Further, mechanical trig-
ger events, in particular minor traumas, may play
a subordinate role in older patients with CeAD as
the arteries may be less susceptible to mechanical
stress given the increased arterial stiffness in older
patients.
Our observation that patients with CeAD aged
$60 often lack pain and mechanical trigger events
—characteristics considered suggestive for CeAD—
indicates the possibility that CeAD might be under-
diagnosed in this age group. Compared to younger
patients, investigations to diagnose CeAD might be
ordered less often in this age group, as CeAD is con-
sidered a disease of young to middle-aged adults and
typical clinical CeAD signs and symptoms seem infre-
quent in those aged $60 years. Signs of CeAD in
routine neurovascular imaging might be subtle. The
likelihood of clinicians missing or overlooking such
subtle signs, or of performing incomplete vascular
imaging, might be increased if clinicians do not con-
sider CeAD as potential cause of symptoms.
In our cohort, patients with CeAD aged $60 had
less favorable outcome than younger patients, which
is in line with findings in ischemic stroke patients
without CeAD.7
A major strength of our study is the large sample
size, which reduces the risks of chance findings and
allows adjustment for potential confounders. Further,
the design of our analyses proves that our findings are
solid: the major results of the IPD were confirmed by
analyses within each separate cohort as well as
by meta-analyses across all 3 cohorts. Moreover, base-
line characteristics and outcomes have been collected
according to standardized criteria irrespective of and
therefore unbiased by the present research question.
Still, we are aware of the following limitations: (1)
the data used in this analysis are based on large
hospital-based cohorts of CeAD patients, which are
non-randomized and were not monitored; (2) the size
of the age groups differs considerably; (3) our dataset
did not comprise information on the presence of
genetic factors, precluding analyses on the role of such
factors in age subgroups or the interaction with
acquired risk factors; and (4) there were no predefined
surveillance procedures in the study cohorts, which
may lead to an ascertainment bias. As a consequence,
the age distribution found in our cohorts may not
represent the true distribution in CeAD. In addition,
differential ascertainment based on different expo-
sures and risk factors in the different age groups might
impair the reliability of our findings on the frequency
of risk factors and clinical characteristics within each
age group. We acknowledge that our data do not
allow us to define strict criteria on which patients
should undergo a specific evaluation for CeAD, in
particular since we did not include a comparison
group of patients without CeAD. For the latter rea-
sons, we were unable to provide data on the frequency
of CeAD in all stroke patients aged $60.
Our analyses of large hospital-based cohorts of pa-
tients diagnosed with CeAD in departments of neu-
rology in tertiary hospitals suggest that in this
setting 1 in 14 patients with CeAD is aged$60 years.
Compared to younger age groups, CeAD in persons
aged $60 years is more often painless and lacking
identifiable mechanical trigger events, which renders
the diagnosis more challenging. As older patients with
CeAD may have less favorable outcomes, it is impor-
tant to be aware of the risk and consider CeAD
among other more frequent stroke subtypes in these
age groups.
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